Proposal regarding new board members and chairman of the board of Genovis

Proposal regarding new board members and chairman of the board of Genovis

Genovs AB (publ) announces that Genovis' nomination committee, proposes two new
board members to be elected at the Annual General Meeting on June 2, 2009.
According to the proposal, Genovis' board would consist of six members with no
alternates.

The new candidates, whose term of office would run until the close of the next
annual general meeting, are and Fredrik Lindgren, CEO Biolin Scientific AB and
Ebba Åsly Fåhraeus, Vice President Sales and Marketing Anoto AB.

Carina Schmidt, Thomas Laurell and Nicklas Gerhardsson are proposed to be
re-elected as board members and Hans Göran Arlock is proposed to be re-elected
as chairman of the board. 

Bo Håkansson, member of the board, has already declared that he will resign from
the board.

Find out more, contact:
Sarah Fredriksson, CEO, Genovis AB
Tel: +46 46 10 12 35
sarah.fredriksson@genovis.com

Genovis is a biotech company on the leading edge of nanotechnology and
nanoparticles. The company's patented nano-induced magnetic transfer (NIMT®)
technology was developed to facilitate effective preclinical research for the
life science industry. Genovis shares are listed on the First North OMX Nordic
Exchange. Mangold Fondkommission is our certified advisor and liquidity
guarantor.